or Try an Advanced Search...

    Clinical Trial Products Stocks List

    Symbol Grade Name % Change
    INCY C Incyte Corporation -0.23
    BIIB F Biogen Idec Inc. 1.02
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Clinical Trial Product Nasdaq 100 Psoriasis S&P 500 Alzheimer's Disease Autoimmune Disorders Biopharmaceutical Biotechnology Cd20 Chemical Compounds Chronic Lymphocytic Leukemia Degenerative Disease Diabetic Nephropathy Disability Hematologic Malignancies Hemophilia Idiopathic Pulmonary Fibrosis Immune Disorders Immunology Immunosuppressants

    Related ETFs - A few ETFs which own one or more of the above listed Clinical Trial Products stocks.

    Symbol Grade Name Weight
    BIS B ProShares UltraShort Nasdaq Biotechnology 8.21
    PBE D PowerShares Dynamic Biotech & Genome 7.56
    FBT D First Trust Amex Biotech Index Fund 6.92
    BBH D Market Vectors Biotech ETF 5.6
    XBI D SPDR S&P Biotech ETF 5.48
    View all Clinical Trial Products ETFs...
    Compare ETFs
    Compare BBH to XBI Compare BIS to FBT Compare FBT to BBH

        Clinical Trial Products Stocks Recent News

        Date Stock Title
        Nov 20 BIIB Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
        Nov 20 BIIB Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 INCY Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict
        Nov 19 INCY Equity Markets Close Mixed Ahead of Nvidia Earnings
        Nov 19 INCY S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing
        Nov 19 INCY Sector Update: Health Care Stocks Decline
        Nov 19 INCY Top Midday Decliners
        Nov 19 INCY Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict
        Nov 19 INCY Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
        Nov 19 INCY Incyte seesaws on report of potential Merck takeover interest
        Nov 19 BIIB Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
        Nov 19 INCY Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study
        Nov 19 INCY Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock.
        Nov 19 INCY Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
        Nov 19 INCY Incyte Faces Challenges but Remains Focused on Strategic Growth
        Nov 19 INCY Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
        Nov 19 INCY Incyte sinks on setback for drugs acquired in $750M buyout
        Nov 19 BIIB Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
        Nov 18 INCY Incyte drops 9% after pausing enrollment in study for urticaria asset
        Nov 18 INCY Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Clinical Trial Product Nasdaq 100 Psoriasis S&P 500 Alzheimer's Disease Autoimmune Disorders Biopharmaceutical Biotechnology Cd20 Chemical Compounds Chronic Lymphocytic Leukemia Degenerative Disease Diabetic Nephropathy Disability Hematologic Malignancies Hemophilia Idiopathic Pulmonary Fibrosis Immune Disorders Immunology Immunosuppressants
        Clinical Trial Products

        Clinical trial products are any products used in clinical trials, such as drugs, medical devices, or biologics. These products are tested in clinical trials to determine their safety and efficacy for treating a particular medical condition. Clinical trial products must meet strict regulatory requirements before they can be approved for use in humans.

        Browse All Tags